Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 2 天前评分45
正文 · 原文
TOMAS2: PARP1 H-score as a Potential Biomarker for Trabectedin + Olaparib in Sarcoma
@OncoAlert #ESMO26 #ESMOAmbassadors #ESMOcommunity @myESMO
6 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA37按 Proffered paper: Gynaecological cancers 对上
Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.org来源：Aya Mohamed | MSc, MD 🎗 · x.com